SOHM, Inc., Unveils Genetically Engineered Ovarian Cancer Cell Line Using ABBIE(TM) Platform to Accelerate GYS1 Drug Discovery
Rhea-AI Summary
SOHM, Inc. (OTC:SHMN) has successfully developed a genetically modified ovarian cancer cell line (SKOV3) that overexpresses the GYS1 gene using their proprietary ABBIE™ platform. This breakthrough provides a valuable tool for screening GYS1 inhibitors, as GYS1 is a crucial enzyme in cellular energy metabolism linked to cancer cell survival. The engineered cell line, SKOV3-GYS1+, offers a ready-to-use system for evaluating GYS1-targeted compounds, particularly relevant for aggressive cancers like ovarian, breast, and pancreatic malignancies.
The ABBIE™ platform enables high-specificity gene editing without viral vectors, and SOHM plans to expand its engineered cell line portfolio for metabolic and immuno-oncology targets throughout 2025.
Positive
- Development of novel SKOV3-GYS1+ cell line enables rapid screening of GYS1 inhibitors
- ABBIE™ platform demonstrates capability for high-efficiency gene editing with low off-target effects
- Company plans portfolio expansion into metabolic and immuno-oncology targets in 2025
Negative
- None.
News Market Reaction
On the day this news was published, SHMN gained 12.50%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CHINO HILLS, CALIFORNIA / ACCESS Newswire / May 6, 2025 / SOHM, Inc. (OTC PINK:SHMN), a biotech company at the forefront of precision cellular engineering, announced today the successful development of a genetically modified ovarian cancer cell line (SKOV3) overexpressing the GYS1 gene, using its proprietary gene editing platform, ABBIE™. This breakthrough establishes a powerful tool for the rapid screening of novel glycogen synthase 1 (GYS1) inhibitors and underscores SOHM's capacity to swiftly generate custom-engineered cell models to support targeted drug development.
GYS1 (glycogen synthase 1) is a pivotal enzyme in cellular energy metabolism, with emerging evidence linking its overexpression to cancer cell survival and immune evasion under metabolic stress. Elevated GYS1 activity has been implicated in tumor adaptation to nutrient-poor environments-particularly in aggressive cancers such as ovarian, breast, and pancreatic malignancies-making it an attractive and underexplored therapeutic target.
"Our new SKOV3-GYS1+ cell line represents a versatile, ready-to-use system for biotech and pharma partners looking to evaluate GYS1-targeted compounds," said Dr. David Aguilar, SOHM's COO. "This is just one example of how ABBIE™ enables the rapid and precise engineering of human cell models to match emerging research priorities."
The ABBIE™ gene editing platform is designed for high specificity and fast turnaround, enabling SOHM to customize cell lines across a range of oncology and rare disease applications. ABBIE™ delivers high efficiency with low off-target effects, streamlining the development of disease-relevant screening models without the need for viral vectors.
SOHM plans to expand its engineered cell line portfolio to include other metabolic and immuno-oncology targets in 2025, aiming to empower early-stage drug developers with physiologically relevant models for high-throughput compound screening.
About SOHM, Inc.
SOHM is a US-based pharmaceutical and biotechnology company focused on developing and manufacturing cutting-edge therapeutic solutions, including cell and gene therapies, to address unmet medical needs globally. With the ABBIE™ gene editing platform, SOHM is unlocking a new era of customized disease models to support drug discovery, from bench to bedside.
Safe Harbor Statement
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
Media Contact:
SOHM, Inc.
714-522-6700
info@sohm.com
SOURCE: SOHM, Inc
View the original press release on ACCESS Newswire
FAQ
What is the significance of SOHM's new GYS1 ovarian cancer cell line?
How does SHMN's ABBIE platform work in gene editing?
What are SOHM's (SHMN) plans for cell line development in 2025?
Why is GYS1 an important target for cancer treatment?
